GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Penumbra Inc (NYSE:PEN) » Definitions » Earnings Yield %

PEN (Penumbra) Earnings Yield % : 0.12% (As of Apr. 10, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Penumbra Earnings Yield %?

The earnings yield is an indication of how much return shareholders' investment in the company earned over the past 12 months. The higher the earnings yield is, the better.

As of today (2025-04-10), the stock price of Penumbra is $275.46. Penumbra's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $0.34. Therefore, Penumbra's earnings yield of today is 0.12%.

The earnings yield does not consider the growth of the business. A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Penumbra's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2024 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Penumbra Earnings Yield % Calculation

Earnings yield is the reciprocal of the P/E Ratio.

Penumbra's Earnings Yield for today is calculated as

Earnings Yield=Earnings per Share (Diluted) (TTM)/Share Price
=0.340/275.46
=0.12 %

Penumbra's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.340 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Earnings Yield=Net Income /Market Cap

The earnings in the calculation is the Trailing Twelve Months earnings.


Penumbra  (NYSE:PEN) Earnings Yield % Explanation

If the P/E ratio is an indication of how many years it takes for the company to earn back the stock price shareholders pay to buy the shares, the earnings yield is an indication of how much return shareholders' investment in the company earned over the past 12 months. The higher the earnings yield is, the better.

If a company loses money, the earnings yield is negative. This gives a more straightforward indication that the company is losing money. This is an advantage of using earnings yield instead of the P/E ratio in valuation. For valuation purposes, the P/B Ratio and the P/S Ratio should be used for companies that are losing money.

Like the P/E ratio, the earnings yield can be used to compare investments in different industries. It can even be used to compare the attractiveness of different asset classes such as bonds and cash. Of course, the earnings yield should not be the only factor in deciding which asset classes to invest.

Also similar to the P/E ratio, the earnings yield does not consider the growth of the business. A growing company with the same earnings yield should be more attractive than a company that has the same earnings yield but does not grow.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %.

Be Aware

Just like the P/E Ratio, non-recurring items such as selling part of the business, selling a previous investment, etc., can affect earnings yield dramatically. The earning yield is also a poor indication for cyclical companies. When a cyclical stock has a high earnings yield it is usually at the peak of its cycle.


Penumbra Earnings Yield % Related Terms

Thank you for viewing the detailed overview of Penumbra's Earnings Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Penumbra Business Description

Traded in Other Exchanges
Address
One Penumbra Place, Alameda, CA, USA, 94502
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products.
Executives
Adam Elsesser director, officer: Chairman, CEO and President 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Lambert Shiu officer: Chief Accounting Officer ONE PENUMBRA PLACE, ALAMEDA CA 94502
Bridget O'rourke director ONE PENUMBRA PLACE, ALAMEDA CA 94502
Johanna Roberts officer: EVP, Gen. Counsel & Secretary PENUMBRA, INC., ONE PENUMBRA PLACE, ALAMEDA CA 94502
Maggie Yuen officer: Chief Financial Officer ONE PENUMBRA PLACE, ALAMEDA CA 94502
Arani Bose director, officer: Chief Innovator 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Harpreet Grewal director C/O VISTAPRINT USA, INCORPORATED, 100 HAYDEN AVE., LEXINGTON MA 02050
Don W. Kassing director 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Surbhi Sarna director ONE PENUMBRA PLACE, ALAMEDA CA 94502
Thomas Wilder director 2 MUSICK, IRVINE CA 92618
Lynn Rothman officer: EVP and Chief Business Officer 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
James Robert Pray officer: President, International 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Sridhar Kosaraju officer: CFO and Head of Strategy 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Janet Leeds director ONE PENUMBRA PLACE, ALAMEDA CA 94502
Robert D. Evans officer: EVP, Gen. Counsel & Secretary ONE PENUMBRA PLACE, 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502

Penumbra Headlines